NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

FibroBiologics, Inc. (FBLG) Stock Analysis

FibroBiologics, Inc. (FBLG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FBLG

$1.81

+$0.05 (+2.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FBLG with… →

FBLG Key Statistics

As of Sep 4, 2026
Trading
Open
$1.73
Previous Close
$1.76
Day's Range
1.71–1.90
52-Week Range
0.62–12.40
Volume
210.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.68
Valuation
Market Cap
$12.05M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.10
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$18.65M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.66M
1-Year Return
−84.76%
Dividend and dates
Avg Volume
215.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FBLG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−59.78%
2025−88.75%
2024−93.13%

As of September 4, 2026.

FBLG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$18.65M—
2024$0.00−$11.16M—
2023$0.00−$16.49M—
2022$0.00−$5.12M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$16.65M−$18.65M—
2024$0.00—−$13.74M−$11.16M—
2023$0.00—−$8.89M−$16.49M—
2022$0.00—−$4.47M−$5.12M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FBLG Valuation vs Biotechnology Median

Median of 656 stocks
MetricFBLGBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

FibroBiologics, Inc. (FBLG) carries a market capitalisation of $12.05M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 15.

FBLG last closed at $1.81 on September 4, 2026. That is +$0.05 (+2.84%) against the previous close. The 52-week range on file runs from $0.62 to $12.40. The latest close sits 191.94% above that 52-week low.

Financial Health

In fiscal 2025, FibroBiologics, Inc. reported revenue of $0.00. The same year closed with a net loss of $18.65M. Profit margin runs at 0%. Trailing earnings per share are −5.1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −84.76%. The stored price history starts on January 31, 2024, and the total return since then is −99.69%. The reported beta is 1.68. Annualized volatility over the trailing 2 years is 123.66%.

Growth & Income

No dividend is on file for FBLG.

The strongest complete calendar year on file is 2025 at −88.75%; the weakest is 2024 at −93.13%. So far in 2026 the price is −59.78%.

Peer Comparison

FibroBiologics, Inc. (FBLG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
FibroBiologics, Inc. FBLG $12.05M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. FibroBiologics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Visit website →